RINGPU(300119) 新浪财经·2025-05-05 10:47Core Viewpoint - The company reported a strong performance in Q1 2025, with revenue and net profit showing significant year-on-year growth, driven by the sales of biological products and strategic acquisitions in the pet sector [1][2]. Group 1: Financial Performance - In Q1 2025, the company achieved revenue of 822 million, a year-on-year increase of 20.00%, and a net profit attributable to shareholders of 116 million, up 28.45% [1]. - The non-recurring net profit reached 93 million, reflecting a growth of 19.65% year-on-year [1]. Group 2: Business Segments - The biological products segment saw substantial growth, with high pathogenic avian influenza vaccine sales reaching 87 million, a 16% increase, and Marek's disease vaccine sales at 26 million, up 59% [1]. - The company’s acquisition of Betway Antai last May contributed to the increase in foot-and-mouth disease vaccine revenue [1]. - The pet segment is expanding, with the acquisition of Zhongrui Supply Chain and the upcoming launch of a new oral deworming product for cats [1][2]. Group 3: Strategic Initiatives - The company established strategic partnerships with large breeding groups to enhance market position and reduce costs for clients [2]. - It is actively pursuing international market expansion, with 35 product registrations completed in seven countries, including Indonesia and Sri Lanka [2]. - The company aims to build a comprehensive ecosystem in the pet sector through collaboration among its core divisions, enhancing its brand presence [2]. Group 4: Product Development - The company launched its self-developed cat trivalent vaccine "Rui Miao Shu," breaking foreign monopolies and becoming the first domestic product in this category [3]. - Future earnings per share (EPS) projections for 2025-2027 are estimated at 0.91, 1.08, and 1.16, with corresponding dynamic price-to-earnings ratios of 23, 19, and 18 [3].